1-7 of 7
Peter Charlton
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ATR Inhibitors VE-821 and VX-970 Sensitize Cancer Cells to Topoisomerase I Inhibitors by Disabling DNA Replication Initiation and Fork Elongation Responses

Rozenn Jossé, Scott E. Martin, Rajarshi Guha, Pinar Ormanoglu, Thomas D. Pfister, Philip M. Reaper, Christopher S. Barnes, Julie Jones, Peter Charlton, John R. Pollard, Joel Morris, James H. Doroshow, Yves Pommier
Journal: Cancer Research
Cancer Res (2014) 74 (23): 6968–6979.
https://doi.org/10.1158/0008-5472.CAN-13-3369
Published: 30 November 2014
View article titled, ATR Inhibitors VE-821 and VX-970 Sensitize Cancer Cells to Topoisomerase I Inhibitors by Disabling DNA Replication Initiation and Fork Elongation Responses
Open the PDF for ATR Inhibitors VE-821 and VX-970 Sensitize Cancer Cells to Topoisomerase I Inhibitors by Disabling DNA Replication Initiation and Fork Elongation Responses in another window
Includes: Supplementary data
Journal Articles

Abstract LB-299: Comprehensive preclinical evaluation of VE-822, the first ATR-targeted drug candidate: a novel approach to transforming the efficacy of DNA damaging agents.

Diane Boucher, Peter Charlton, Jean-Damien Charrier, Brinley Furey, Yong Gu, Amy Hall, Brian Hare, Howard Li, Sean Milton, Cheryl Murphy, Philip Reaper, Darin Takemoto, Taturo Udagawa, Yuxin Wang, Mark Wood, John Pollard
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): LB-299.
https://doi.org/10.1158/1538-7445.AM2013-LB-299
Published: 15 April 2013
View article titled, Abstract LB-299: Comprehensive preclinical evaluation of VE-822, the first ATR-targeted drug candidate: a novel approach to transforming the efficacy of DNA damaging agents.
Journal Articles

Abstract 5501: Evaluation of the first potent and highly selective inhibitor of ATR kinase: An approach to selectively sensitize cancer cells to ionizing radiation and hypoxia

Gillies McKenna, Thomas Brunner, Peter Charlton, Emmanouil Fokas, Ester Hammond, Matthew Mangan, Monica Olcina, Isabel Pires, John Pollard, Remko Prevo, Philip Reaper
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 5501.
https://doi.org/10.1158/1538-7445.AM2011-5501
Published: 15 April 2011
View article titled, Abstract 5501: Evaluation of the first potent and highly selective inhibitor of ATR kinase: An approach to selectively sensitize cancer cells to ionizing radiation and hypoxia
Journal Articles

Abstract 3339: A role for CXCR4 signalling in the regulation of normal and malignant breast stem cell activity

Matthew Ablett, Yasushi Kojima, Peter Charlton, Akira Orimo, Robert Clarke
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 3339.
https://doi.org/10.1158/1538-7445.AM2011-3339
Published: 15 April 2011
View article titled, Abstract 3339: A role for CXCR4 signalling in the regulation of normal and malignant breast stem cell activity
Journal Articles

Abstract 5491: Evaluation of the first potent and highly selective inhibitor of ATR kinase: An approach to selectively sensitize cancer cells to genotoxic drugs

John R. Pollard, Paul Caron, Peter Charlton, Jean-Damien Charrier, Julian Golec, Matthew Griffiths, Amy Hall, Brian Hare, Joanna Long, Somhairle MacCormick, Sean Milton, Mark Murcko, Cheryl Murphy, Adele Peek, Philip Reaper, Darin Takemoto
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 5491.
https://doi.org/10.1158/1538-7445.AM2011-5491
Published: 15 April 2011
View article titled, Abstract 5491: Evaluation of the first potent and highly selective inhibitor of ATR kinase: An approach to selectively sensitize cancer cells to genotoxic drugs
Journal Articles

A novel inhibition mechanism of Aurora kinases by the MK-0457 (VX-680) class of compounds confers potent cell activity and an advantageous pharmacodynamic profile

Peter Charlton, James Westcott, Phillip Reaper, Mark Anderton, Peter Weber, Graham Cheetham, John Pollard
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): LB-374.
Published: 01 May 2007
View article titled, A novel inhibition mechanism of Aurora kinases by the MK-0457 (VX-680) class of compounds confers potent cell activity and an advantageous pharmacodynamic profile
Journal Articles

In Vitro and in Vivo Reversal of P-Glycoprotein-mediated Multidrug Resistance by a Novel Potent Modulator, XR9576

Prakash Mistry, Alistair J. Stewart, Wendy Dangerfield, Sade Okiji, Chris Liddle, Douglas Bootle, Jane A. Plumb, David Templeton, Peter Charlton
Journal: Cancer Research
Cancer Res (2001) 61 (2): 749–758.
Published: 01 January 2001
View article titled, <em>In Vitro and in Vivo</em> Reversal of P-Glycoprotein-mediated Multidrug Resistance by a Novel Potent Modulator, XR9576
Open the PDF for <em>In Vitro and in Vivo</em> Reversal of P-Glycoprotein-mediated Multidrug Resistance by a Novel Potent Modulator, XR9576 in another window